Global Anti-Anemic Drug Market was valued at US$14.070 billion in 2019. An anti-anemia drug is used for curing anemia. Anemia is a condition in which there is a low number of red blood cells in the patients. Having low anemia can result in multiple organ failure due to a lack of oxygen being provided to them. Symptoms of anemia are fatigue or pain. Women, young children, and people with long term disease are more likely to have anemia. Anemia can be caused by blood loss, decreased or faulty red blood cell production, and by the destruction of red blood cells. The anti-anemic drug is used for solving these issues in patients.
The global anti-anemic drug market is growing due to the increasing anemic patients and the growing geriatric population. According to the World Bank Data, the global aging population (people aged 65 and above) from 7.49% of the total population in the world in the year 2009 to 8.87% of the total world population in the year 2018. The increase in old people aged 65 and above is due to improved health facilities around the world and people living a better lifestyle that includes better food quality and other facilities required for living. The improvement in medication and drugs is also a factor for the geriatric population. This is further increasing the demand for anti-anemic drugs.
Factors such as the increase in road accidents, rising cases of cancer, induced stress, poor nutritional habits, diabetes, rise in lactating, etc. are increasing the demand for anti-anemic drugs across the world. The government efforts to curb anemia by spreading awareness by launching a health campaign and providing medicines to poor people at low cost is further contributing to the market growth of anti-anemic drug during the forecast period.
The global anti-anemic drug market is segmented by anemia type, route of administration, and by geography. On the basis of anemia type, the market is segmented as iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia, pernicious anemia, and others. The market segmentation based on the route of administration is done as oral and injection.
Growing Anemia prevalence around the world the major factor
The increasing prevalence of anemia is increasing the demand for anti-anemic drugs. According to the World Health Organization (WHO), 800 million children and women were affected by anemia globally in 2011. The increasing unhealthy lifestyle, a high number of women of reproductive age, and complications during pregnancy majorly in developing countries are the factor for the increasing demand for anti-anemic drugs. According to the World Bank data, the prevalence of anemia among pregnant women ranged from 40.2% in 2006 to 39.3% in 2011 which was increased to 40.1% in 2016. This increasing percentage of anemia among pregnant women is an alarming factor. Furthermore, the prevalence of anemia among children under 5 was 44.2% in 2005 reduced to 41.4% in 2014 but rose again to 41.7% in 2016. This increase in anemia in children under 5 is due to non-healthy food habits and poverty among most of the developing countries in the world.
By geography, Asia Pacific has a significant share in the market
Regionally, the global anti-anemic drug market is classified into North America, South America, Europe, Middle East and Africa (MEA), and Asia Pacific (APAC). The Asia Pacific anti-anemic drug market is expected to have a significant share in the global anti-anemic drug market due to the high prevalence of anemia patients in the region. The increase in government expenditure on healthcare facilities and increasing health awareness among people is driving the anti-anemic drug market in the Asia Pacific region. The increasing advancement in technology and the growing pharmaceutical industry in the Asia Pacific region is projected to further contribute to the growing anti-anemic drug market across the region. North America and Europe hold notable market share in the global anti-anemic drug market due to the presence of large pharmaceutical companies and high health awareness among people in the region. The increasing research and development in the pharmaceutical industry will further bolster the market growth of anti-anemic drugs across these regions during the forecast period.
Prominent key market players in the Global Anti-anemic Drug Market include Amgen Inc., GlaxoSmithKline plc., Global Blood Therapeutics, Inc.,Akebia Therapeutics, Pieris Pharmaceuticals, Inc., Acceleron Pharma, Biocon, FibroGen, Inc., and Astellas Pharma Inc. These companies hold a noteworthy share in the market on account of their good brand image and product offerings. Major players in the Anti-anemic Drug Market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.
December 2019:- The FibroGen submitted a new drug application to the U.S. FDA for Roxadusat in patients with anemia of Chronic Kidney Disease in both non-dialysis-dependent (NDD) and dialysis-dependent (DD) CKD patients. It is the first orally administered small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor submitted for FDA regulatory approval for the treatment of anemia of CKD.
November 2019: Acceleron got its new medicine REBLOZYL® (luspatercept-aamt) approved by the FDA. It is for treating Anemia in adults with Beta-Thalassemia. It is the first and only FDA approved erythroid maturation agent, representing a new class of therapy for patients who require regular Red Blood Cell transfusions.
November 2019: The Global Blood Therapeutics, Inc. got the FDA approval for its Oxbryta™ (Voxelotor). It is the first medicine that specifically targets the root cause of Sickle Cell disease in adults and children 12 years of age or older.
September 2019: Evrenzo (Roxadustat) Tablets for chronic kidney disease in dialysis patients were approved by the Ministry of Health, Labour and Welfare (MHLW) of Japan. It is the first orally administered in the inhibitor of hypoxia-inducible factor (HIF) prolyl-hydroxylase that corrects anemia by a mechanism of action that is different from that of erythropoiesis-stimulating agents (ESAs).
December 2018: AstraZenca announced that its partner, FibroGen Medical Technology Development Co., Ltd (FibroGen China) received formal marketing authorization from the National Medical Products Administration (NMPA) for Roxadustat in China. This medicine can be prescribed to patients who use peritoneal dialysis or hemodialysis.